FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
The Food and Drug Administration (FDA) has granted 510(k) clearance for BrainSpec Core™, a magnetic resonance spectroscopy (MRS) software that utilizes a reference base of brain chemistry to help detect a variety of common brain-related conditions ranging from epilepsy and brain tumors to Alzheimer’s disease.
Employing advanced signal processing methods, BrainSpec Core offers insight into the chemical composition of brain tissue and measurement of metabolite levels in the brain, according to BrainSpec, the developer of the software.
The company pointed out that BrainSpec Core has demonstrated an 85 percent sensitivity rate and a 90 percent specificity rate for the oncometabolite 2-hydroxyglutarate, which is present in low-grade gliomas.
“(The) ability to measure 2-hydroxyglutarate and other brain metabolites provides a direct and non-invasive marker of low-grade gliomas that could lead to a more accurate classification of individual tumors benefitting decision making,” noted Raymond Y. Huang, M.D., Ph.D, the division chief of neuroradiology at Brigham and Women's Hospital.
BrainSpec added that BrainSpec Core can be utilized with 3T MRI scanners from GE HealthCare, Siemens Healthineers and Philips.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
